[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IN2012DN01684A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01684A
IN2012DN01684A IN1684DEN2012A IN2012DN01684A IN 2012DN01684 A IN2012DN01684 A IN 2012DN01684A IN 1684DEN2012 A IN1684DEN2012 A IN 1684DEN2012A IN 2012DN01684 A IN2012DN01684 A IN 2012DN01684A
Authority
IN
India
Prior art keywords
malaria
malaria infection
mammal
compounds
transmission
Prior art date
Application number
Inventor
Xin-Zhuan Su
Jing Yuan
Dipak Raj
Sittiporn Pattaradilokrat
Ron Johnson
Ruili Huang
Original Assignee
U S A Represented By The Secretary Dept Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by U S A Represented By The Secretary Dept Of Health And Human Services filed Critical U S A Represented By The Secretary Dept Of Health And Human Services
Publication of IN2012DN01684A publication Critical patent/IN2012DN01684A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)

Abstract

The invention provides methods and compounds for the treatment and prevention of malaria infection and transmission in a mammal by administering compounds of the invention to a mammal having or suspected of having a malaria infection. The invention also provides pharmaceutical compositions that can kill or arrest the growth of Plasmodium organisms, and especially Plasmodium falciparum, thereby preventing or blocking transmission of malaria as well as treating malaria infection.
IN1684DEN2012 2009-08-27 2010-08-27 IN2012DN01684A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23741709P 2009-08-27 2009-08-27
PCT/US2010/047019 WO2011025969A1 (en) 2009-08-27 2010-08-27 Compounds that treat malaria and prevent malaria transmission

Publications (1)

Publication Number Publication Date
IN2012DN01684A true IN2012DN01684A (en) 2015-06-05

Family

ID=43628406

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1684DEN2012 IN2012DN01684A (en) 2009-08-27 2010-08-27

Country Status (6)

Country Link
US (2) US9375424B2 (en)
EP (1) EP2470013A4 (en)
CN (1) CN102595894A (en)
CA (1) CA2772085A1 (en)
IN (1) IN2012DN01684A (en)
WO (1) WO2011025969A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9187439B2 (en) 2011-09-21 2015-11-17 Inception Orion, Inc. Tricyclic compounds useful as neurogenic and neuroprotective agents
WO2013082469A2 (en) * 2011-12-02 2013-06-06 University Of Vermont And State Agricultural College Methods and compositions for treating infections
WO2014031872A2 (en) * 2012-08-23 2014-02-27 The Broad Institute, Inc. Small molecule inhibitors for treating parasitic infections
WO2014113495A1 (en) 2013-01-15 2014-07-24 The Trustees Of Columbia University In The City Of New York Activation or reactivation of ache
WO2017050297A1 (en) * 2015-09-25 2017-03-30 Sun Jet Biotechnology Inc. Combination therapy for ev71 infection
US10562922B2 (en) 2016-02-19 2020-02-18 Council Of Scientific And Industrial Research Silicon based cyclic compounds and pharmaceutical compositions for treating malaria and toxoplasmosis
GB2587951B (en) * 2018-04-26 2023-03-08 Cas Lamvac Guangzhou Biomedical Tech Co Ltd Attenuation system and use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5373005A (en) 1988-04-20 1994-12-13 Merrell Dow Pharmaceuticals Inc. Despiramine in the treatment of drug-resistant malarial infections
US5853739A (en) 1988-05-02 1998-12-29 The United States Of America As Represented By The Department Of Health And Human Services Transmission-blocking vaccine against malaria
DE3821392A1 (en) * 1988-06-24 1989-12-28 Nattermann A & Cie NEW PHARMACEUTICAL USE OF 2-PHENYL-1,2-BENZISOSELENAZOLE-3 (2H) -ONEONE (EBSELEN)
US5021426A (en) 1990-02-26 1991-06-04 Merck & Co., Inc. Method of traeting malaria with cyproheptadine derivatives
MX9606382A (en) * 1994-06-17 1997-03-29 Hoffmann La Roche N,n'-bis(quinolin-4-yl)-diamine derivatives, their preparation and their use as antimalarials.
US7056911B1 (en) * 1999-01-26 2006-06-06 Dana-Farber Cancer Institute Dibenz[B,F]azepine compounds, pharmaceutical compositions comprising same and methods of use thereof
AU2001281403A1 (en) 2000-08-08 2002-02-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for inhibiting transmission of malaria
JP4189472B2 (en) 2000-11-22 2008-12-03 勤 竹内 Dibenzosuberanyl piperazine derivative and drug resistance overcoming agent containing the derivative
US7670631B2 (en) 2003-03-12 2010-03-02 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Method for the prevention of malaria infection of humans by hepatocyte growth factor antagonists
DE10353186A1 (en) 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Multilayer dosage form containing a modulatory substance in relation to the release of active ingredient
TW200615273A (en) 2004-11-10 2006-05-16 Nicholas Piramal India Ltd Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha
WO2008064011A1 (en) 2006-11-13 2008-05-29 The Government Of The U.S. Of America As Represented By The Department Of Veterans Affairs Acridone compounds
WO2009026858A1 (en) 2007-08-28 2009-03-05 Centro De Quimica Farmaceutica Derivatives of acridinone as anti-parasitic, anti-fungal and anti-viral agents

Also Published As

Publication number Publication date
WO2011025969A1 (en) 2011-03-03
CN102595894A (en) 2012-07-18
US20120196882A1 (en) 2012-08-02
US20160303103A1 (en) 2016-10-20
CA2772085A1 (en) 2011-03-03
EP2470013A1 (en) 2012-07-04
US9375424B2 (en) 2016-06-28
EP2470013A4 (en) 2013-05-01

Similar Documents

Publication Publication Date Title
DOP2021000147A (en) THERAPEUTIC COMBINATION COMPRISING LAMIVUDINE
EA201200355A1 (en) METHODS OF PREVENTION AND TREATMENT OF ISCHEMIA OF THE BRAIN
IN2012DN01684A (en)
EA201001847A1 (en) COMPOUNDS AND COMPOSITIONS APPLICABLE FOR THE TREATMENT OF MALARIA
IN2012DN00624A (en)
NZ703064A (en) Inhibitors of hepatitis c virus
EP2493464A4 (en) Methylsulfonylmethane (msm) for treatment of drug resistant microorganisms
MX2013003634A (en) Polycyclic heterocycle derivatives and methods of use thereof for the treatment of viral diseases.
WO2010057101A3 (en) Compounds useful as hiv blockers
UA116765C2 (en) (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
TN2010000137A1 (en) Spiropyrrolidines and their use against hcv and hiv infection
SG178952A1 (en) Chemical compounds
MY161495A (en) Virus like particle compositions and methods of use
EA200970542A1 (en) ACTION INHIBITORS Akt
EA201200098A1 (en) CONDENSED IMIDAZOLES AND CONTAINING THEIR COMPOSITIONS INTENDED FOR THE TREATMENT OF PARASITIC DISEASES, SUCH AS MALARIUM
IN2012DN00971A (en)
SG179082A1 (en) Method for the preparation of an influenza virus
UA110213C2 (en) Use of sigma-ligand induced opioid hyperalgesia
MX350746B (en) Novel cyclosporin derivatives for the treatment and prevention of a viral infection.
MX2014015884A (en) Triazole compounds as antivirals.
MX342832B (en) Treatment or prevention of infection.
MY172788A (en) Influenza vaccines
NZ610547A (en) Novel monensin derivatives for the treatment and prevention of protozoal infections
MX2013003903A (en) New treatments of hepatitis c virus infection.
MX2010002679A (en) Deuterated 4 -oxoquinoline derivatives for the treatment of hiv infection.